Exagen (XGN) Cost of Revenue (2018 - 2026)

Exagen (XGN) has 9 years of Cost of Revenue data on file, last reported at $7.1 million in Q1 2026.

• Quarterly Cost of Revenue rose 11.39% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.5 million (up 23.45% YoY) and the FY2025 annual result came in at $27.8 million, up 23.29% from the prior year.
• Cost of Revenue slipped to $7.1 million in Q1 2026, from $7.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $7.4 million in Q4 2025 to a low of $5.2 million in Q4 2024.
• A 5-year average of $6.2 million and a median of $6.0 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue fell 10.92% — and 2025, when it surged 43.4%.
• Tracing XGN's Cost of Revenue over 5 years: stood at $6.3 million in 2022, then dropped by 10.92% to $5.6 million in 2023, then slipped by 7.86% to $5.2 million in 2024, then surged by 43.4% to $7.4 million in 2025, then fell by 4.36% to $7.1 million in 2026.
• The last three Cost of Revenue figures came in at $7.1 million (Q1 2026), $7.4 million (Q4 2025), and $7.2 million (Q3 2025), per Business Quant data.